Matsumoto Rikio, Kuroda Toru, Yamada Hirofumi, Hasegawa Kumi, Mamiya Yutaka, Kon Akira
Department of Surgery, Sekishindo Hospital.
Gan To Kagaku Ryoho. 2009 Nov;36(12):2207-9.
We examined efficacy and safety of bevacizumab (BV)+modified FOLFOX6 (mFOLFOX6) regimen for unresectable colorectal cancer. We had 16 patients: liver metastases 8, lung metastases 4, local recurrences 2, and lymph node metastases 2, as for evaluable lesions. The response rate was 46.6%, and disease control rate was 86.6%. Hepatic metastatectomy was done in two cases after PR response. There was 1 infusion related reaction case, 1 tumor bleeding and 1 anal fistula as the adverse events. In conclusion, the BV+mFOLFOX6 is one of the effective and feasible regimens for unresectable colorectal cancer.
我们研究了贝伐单抗（BV）联合改良FOLFOX6（mFOLFOX6）方案治疗不可切除结直肠癌的疗效和安全性。我们有16例患者，就可评估病灶而言，肝转移8例，肺转移4例，局部复发2例，淋巴结转移2例。缓解率为46.6%，疾病控制率为86.6%。2例患者在PR反应后进行了肝转移灶切除术。不良事件包括1例输液相关反应、1例肿瘤出血和1例肛瘘。总之，BV+mFOLFOX6是治疗不可切除结直肠癌的有效且可行的方案之一。
